Skip to main content

Resiliva 80 mg & 100 mg (Resmetirom)

Resmetirom can cause adverse reactions ranging from relatively common gastrointestinal symptoms to potentially serious liver and gallbladder complications. The frequency and severity can vary among patients.

Common adverse reactions

Current U.S. labeling identifies the following adverse reactions as occurring in at least 5% of patients and more often than placebo:

  • Diarrhea
  • Nausea
  • Pruritus
  • Vomiting
  • Constipation
  • Abdominal pain
  • Dizziness

The EMA likewise identifies diarrhea and nausea among the most common adverse effects.

Important serious risks

RiskWhy it matters
HepatotoxicityLiver injury can occur
Gallbladder-related eventsCholelithiasis and cholecystitis have been reported
Drug interactionsResmetirom can affect or be affected by several medicines

Warning signs

Patients should promptly discuss concerning symptoms with their healthcare professional. Symptoms such as jaundice, dark urine, significant abdominal pain, persistent vomiting or other signs of liver or gallbladder disease may require medical evaluation.

Monitoring

Clinical assessment may include liver-related symptoms and laboratory testing. The appropriate monitoring schedule depends on the patient’s clinical circumstances.